Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05603715
PHASE2

Pyridostigmine for the Treatment of Constipation in Parkinson Disease

Sponsor: University of Vermont Medical Center

View on ClinicalTrials.gov

Summary

Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments. Studies suggest that constipation can affect quality of life to a significant degree, in many cases just as much as motor symptoms. There is an unmet need for effective treatment options for constipation in this patient population. The goal of this study is to determine the efficacy and safety of pyridostigmine as a treatment for chronic constipation in patients with PD.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2022-08-10

Completion Date

2026-12-31

Last Updated

2026-02-23

Healthy Volunteers

No

Interventions

DRUG

Pyridostigmine Bromide

Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks

Locations (1)

University of Vermont Medical Center

Burlington, Vermont, United States